Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment. We investigated here whether trastuzumab activity on the growth of HER2-overexpressing BT474 cells may interfere with human periphe...

Full description

Bibliographic Details
Main Authors: Dmitrii Kamashev, Nina Shaban, Maria Suntsova, Mikhail Raevskiy, Victor Efimov, Aleksey Moisseev, Maxim Sorokin, Anton Buzdin
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
trastuzumab
targeted therapy
HER2 overexpression
ERBB2 amplification
BT474
breast cancer
Online Access:https://www.mdpi.com/2227-9059/10/8/1914

Internet

https://www.mdpi.com/2227-9059/10/8/1914

Similar Items